1. Introduction {#sec1}
===============

Egypt was completely lacking incidence rates at national level until the results given in the current report were obtained. Available statistics were proportions derived from single or multicenter hospital registries that could not be used for calculation of incidence rates \[[@B1]--[@B7]\]. The only published incidence rates are those from a cancer registry in one district in Nile delta (Gharbiah governorate). The last internal reports of this registry are for 2002 \[[@B8], [@B9]\]. Incidence rates up to 2007 were published in Volumes IX and X of Cancer Incidence in Five Continents \[[@B10], [@B11]\], date of end of registry activities due to failure of sustainability. The published crude and age-standardized incidence rates from that registry are 96.5 and 132.6/100,000 males and 97.3 and 122.1/100,000 females. The commonest sites of cancer in males are liver (18.7%), bladder (12.7%), non-Hodgkin\'s lymphoma (11.0%) and trachea, bronchus, and lung (8.2%). The 4 sites represent 50.6% of all cancer in males. The commonest sites in females are breast (38.8%), non-Hodgkin\'s lymphoma (8.5%), liver (4.6%), and ovary (4.5%); all together represent 56.4% of cancer in females. There is no mention of rates of both sexes together. Studies are published using these Gharbiah data up to 2007 and are limited to specific sites of cancer mainly breast \[[@B12]--[@B15]\], gastrointestinal \[[@B16]--[@B18]\], hematopoietic \[[@B19]\], bladder \[[@B20]\], and gynecological cancers \[[@B21]\]. None of these geographically-limited studies and published rates could be considered as representative of Egypt, being based on results of one registry in a single delta governorate and do not have an impact on understanding the current situation of cancer at the national level.

The National Cancer Registry Program (NCRP) was established in 2008 and became the only source for cancer incidence in the country \[[@B22]\]. The main objective of the current publication is to present the incidence rates of cancer in Egypt in 2008--2011 based upon data of the National Cancer Registry Program of Egypt with estimated incidence of the disease up to 2050.

2. Materials and Methods {#sec2}
========================

For registration purposes, Egypt was stratified into 3 geographical strata (regions), namely, Lower Egypt (north of Cairo), Middle Egypt (south of Cairo), and Upper Egypt (further south, reaching the southern frontier of the country). The current report covered three districts (governorate), each representing one of the 3 regions, namely, Damietta (Nile delta), Minya (Middle Egypt), and Aswan (Upper Egypt) ([Figure 1](#fig1){ref-type="fig"}). A population-based registry was established in each of the 3 governorates, located in the Ministry of Health Cancer Center.

Trained medical doctors in the 3 registries abstracted records from their cancer centers and regularly visited establishments that dealt with cancer within the governorate for active data collection from medical records. Other sources of data were major tertiary centers on the national level as the National Cancer Institute of Cairo University, Pediatric Oncology Hospital in Cairo, and South Egypt Cancer Institute of Assiut University. Data managers in these institutions reported incident cancer cases among residents of the 3 governorates that were diagnosed/treated in these institutions. Health Insurance Organization and the Government-Subsidized Treatment Program periodically supplied their data. Death registers in local health directorates were regularly checked for cancer deaths from the 3 governorates.

A web-based software was developed for online data entry, validity checks, and data analysis. The database was centralized in the Ministry of Communication and Information Technology server ([Figure 2](#fig2){ref-type="fig"}) with backups in the Ministry of Health and the National Cancer Institute. Computer checks were achieved using DEPedits Conversion and Check Programs for Cancer Registries software \[[@B23]\]. Duplicates were eliminated using the National Identification Number and a clean database was achieved ready for analysis. Registration covered all invasive cancers (behavior code/3), in situ breast cancer (topography code C50.\_ and behavior code/2), in situ urinary bladder cancer (topography code C67.\_ and behavior code/2), and borderline tumors of the brain (topography code C71.\_ and behavior code/1) \[[@B24]\].

For the current report, we used data from Aswan (2008), Minya (2009), and Damietta (2009--2011) to represent the 3 geographical strata of Egypt ([Table 1](#tab1){ref-type="table"}). Crude, age-specific, and world population age-standardized incidence rates were calculated and expressed/100,000 population. Statistics were published at the level of the 3-character ICD-10 codes \[[@B10]\]. The format of IARC publication: "Cancer Incidence in Five Continents, Vol. X" \[[@B11]\], was used for grouping of ICD codes. Statistics for all sites of cancer were expressed twice, with and without nonmelanoma skin cancer (C44). Confidence intervals were calculated following SEER methodology \[[@B25]\].

We developed a model to use incidence data of the population-based registries of the 3 regions (Lower, Middle, and Upper Egypt) to get incidence rates for the entire country. The first step was to apply the age-specific incidence rates of each registry to the population of the stratum it represented to get the number per gender of incident cases in different age groups and for all ages together in this region using data of Egypt last census \[[@B26]\]. Then, we used these statistics to estimate the crude and age specific incidence rates (ASIR) of cancer in the 3 regions together, considered to be representative of the entire country. These rates were applied to the total population of Egypt to get number of incident cancers and crude rate and ASR (world) at national. This procedure was applied for each cancer site and for all sites together per gender. For projections up to 2050, the ASIRs were applied to the projected population of the corresponding year to get the number of patients/age group. Crude and ASR (world) could then be obtained. Steps of calculations are detailed in the Appendix.

3. Results {#sec3}
==========

3.1. National Incidence Rates and Proportions {#sec3.1}
---------------------------------------------

The crude incidence rates on the national level for all sites excluding nonmelanoma skin cancer (C44) were 113.1/100,000 (both sexes), 115.7/100,000 (males), and 110.3/100,000 (females). The age-standardized rates (world) were 166.6/100,000 (both sexes), 175.9/100,000 (males), and 157.0/100,000 (females) as shown in [Table 2](#tab2){ref-type="table"}. Proportions, crude, age standardized incidence rates and detailed age-specific rates of cancer sites according to ICD-10 format are shown in Tables [3](#tab3){ref-type="table"} and [4](#tab4){ref-type="table"} for individual sites of cancer and for all sites together by gender. The age-specific rates are represented graphically in [Figure 3](#fig3){ref-type="fig"} for all cancers and Figures [4](#fig4){ref-type="fig"}, [5](#fig5){ref-type="fig"}, and [6](#fig6){ref-type="fig"} for breast, liver, and bladder cancer as examples of some of the more frequent cancer sites.

[Table 5](#tab5){ref-type="table"} depicts the proportions and rates of the most frequent cancer sites by gender. There was predominance of liver, breast, and bladder cancer that represented approximately 46% of all cancers. Liver and bladder cancers represented approximately 44% of cancer in males. In females, breast and liver cancer occupied the top ranks accounting for around 45% of all cancers.

3.2. Frequencies and Incidence Rates/Geographical Strata {#sec3.2}
--------------------------------------------------------

The frequencies of individual sites of cancer and their incidence rates by geographical stratum and sex are detailed in Tables [6](#tab6){ref-type="table"} and [7](#tab7){ref-type="table"}. [Table 8](#tab8){ref-type="table"} depicts the most common sites of cancer that accounted for approximately 3/4 of cases. For the 2 sexes together, the top 2 ranks in the 3 regions were liver and breast cancer. The proportions and ASR of liver cancer were highest in Lower Egypt (29.6% and 56.8/100,000), less in Middle, and least in Upper Egypt (8.2% and 13.1/100,000).

Among males in the 3 regions, liver and bladder cancer occupied the top 2 ranks. The proportion and ASR of liver cancer were highest in Lower Egypt (41.7% and 81.0/100,000) and lowest in Upper Egypt (11.8% and 17.5/100,000). Cancer of the lung occupied the third or fourth ranks representing 5--7% of cancers and Non-Hodgkin lymphoma was among the 5 most common cancers in Lower Egypt only having a proportion of 6.0% and ASR 10.3/100,000.

Among females, the pattern in the 3 regions was dominated by the high frequency of breast cancer and liver cancer. Proportion of liver cancer was highest in Lower Egypt (16.4%), less in Middle Egypt, and lowest in Upper Egypt (8.9% and 5.1% resp.).

3.3. Estimated Number of Incident Cancer Cases 2013--2050 {#sec3.3}
---------------------------------------------------------

During the period 2013--2050, population of Egypt is expected to increase to approximately 160% the 2013 population size. Applying the current age-specific incidence rates to successive populations would lead to a progressive increase in number of incident cases from 114,985 in 2013 to 331,169 in 2050, approximately 290% of 2013 incidence ([Table 9](#tab9){ref-type="table"} and [Figure 7](#fig7){ref-type="fig"}). This increase reflected both population growth and demographic change mainly due to ageing of population. Population growth alone would increase the number of incident cases by 55.2% in 2015. This fraction progressively decreased to become 32.8% in 2050. The fraction due to ageing gradually increased to reach 67.2% in 2050 ([Figure 8](#fig8){ref-type="fig"}).

4. Discussion {#sec4}
=============

When the National Cancer Registry Program of Egypt was designed, there had been a number of challenges that were addressed. One of the most important challenges was design of a sample that could be representative of such a big country. Other challenges included complete capture of incident cancer cases among residents of selected governorates and best guarantee of quality of data and sustainability of the program to avoid going through survey-like data collection that need to be repeated, a methodology that proved to be inappropriate \[[@B27]\].

Dealing with population-based registration, the word national might be confusing. Actually, and with the exception of very few examples mainly old registries like that of Denmark and registries in small countries like Singapore, complete national coverage is not accomplished \[[@B27], [@B28]\]. The US is an example of a huge country with 18 population-based registries spread over the states without a central national registry \[[@B29]\]. Recently, national incidence rates of Turkey were published based on results of 8 geographically spread peripheral registries \[[@B30]\].

With this in mind, Egypt was geographically stratified for registration purposes into 3 regions: Lower Egypt, to the north of Cairo, and Middle, and Upper Egypt to the south. Three governorates were selected from the 3 regions representing 20.9% of the total population of Egypt. The greater Cairo, including the capital city, and Alexandria, the second capital (approximately 18 million population), were not included in the program due to difficulty in data collection and coverage of a population that daily migrates in and out of these 2 regions. Other regions that were not covered were frontier governorates; namely Matrooh, New Valley, Red Sea, and Sinai, together representing 3.3% of total population \[[@B26]\]. This exclusion was due to logistic reasons being mainly inhabited by nomads or internal migrants working in the tourist industry.

To ensure complete coverage of incident cancer patients in the selected governorates, data were actively collected from medical records of oncology centers within the governorates and from national referral centers like National Cancer Institute in Cairo. Registration covered health-insured patients and patients treated on government-subsidized treatment program would minimize under registration considered a point of strength of the registry. Also, regular check of death registers helped to decrease the possibility of under registration. Death certificate only cases (DCO) accounted for almost 8% of cases which could be considered an acceptable level for a newly established registry \[[@B28]\].

One of the elements that contributed to the National Cancer Registry Program of Egypt was the use of a unique national identification number for duplicate elimination to prevent over registration, which is a serious threat to population-based registries \[[@B7], [@B28]\]. A major concern during the development of a cancer registry especially population-based, is its sustainability. An alternative that was applied in Europe and the US was to conduct successive cancer surveys as with the US Health Interview and Examination surveys. Evaluation of these surveys was negative and this method was not recommended \[[@B28]\]. The main reason for lack of sustainability is unavailability of needed funding and lack of collaboration of treating physicians \[[@B28]\]. From the very beginning, the national cancer registry was planned to be a national program and not a project with start and end dates. During all stages of its development it was gradually incorporated within the infrastructure of the health system to gradually become part of everyday routine work \[[@B31]\]. Quality of data was assured through computer validation and regular manual checks on the peripheral and central levels.

We also developed a mathematical model to apply the regional age-specific incidence rates to the corresponding population structure to get national estimates of all cancers and for individual cancer sites for any specified year. Mathematical modeling is a common practice used to estimate national rates from statistics of regional registries. Recently, a model was developed for china to get national rates based upon regional registries \[[@B32]\]. The advantage of our Egyptian model was use of Egyptian national population-based data without importing data of adjacent countries \[[@B33]\].

Nonetheless, the program has its points of weakness. The data should be carefully interpreted in view of the short initial phase of registration that would be of better accuracy on successive years \[[@B28]\]. Furthermore, some private patients that are not covered by the Government-Subsidized Treatment Program might escape registration. This would be assumed to be a small proportion. With the rising cost of cancer treatment, most patients would seek government financial support which is a constriction right.

The results given in the current report are the first ever published incidence rates on a national and regional level for Egypt derived from a population-based cancer registry program. These incidence rates would replace the proportions that have always been derived from hospital-based results \[[@B1]--[@B5]\]. The results were those of Damietta (Lower Egypt), Minya (Middle Egypt), and Aswan (Upper Egypt). Damietta was selected to represent the Nile delta instead of Gharbiah registry that stopped its activities before establishment of the NCRP and needed some time to be restructured to join the program. Results of these governorates were used to compute regional rates that were used to get a national estimate based upon age-specific incidence rates and population structure.

The estimated incidence rates showed differences between the 3 regions that were mainly in the incidence of liver and bladder cancers. Among males, the proportion of incident liver cancer was highest in Lower Egypt (41.7%) and next in Middle Egypt (20.4%) and lowest in Upper Egypt (11.8%). Bladder cancer ranked next to liver cancer in Lower Egypt (8.8%). In Middle Egypt, the proportion was 14.2%, still lower than liver cancer. In Upper Egypt, liver cancer was still the most common cancer, with a small difference from bladder cancer (12.6%). These differences could be attributed to the high prevalence of hepatitis C viral infection (HCV), which is one of the highest prevalence rates worldwide \[[@B34], [@B35]\]. The distribution of liver cancer in the 3 regions followed the distribution of HCV, which is more frequent in Nile delta with decreasing prevalence going south \[[@B34]\]. The main risk factor for bladder cancer in Egypt was urinary Schistosomiasis which was more frequent in Upper Egypt and its prevalence decreased when going north \[[@B34]\]. Despite control of Schistosomiasis, its effect on bladder cancer needs time to disappear. Another difference between the 3 regions was the proportion of non-Hodgkin lymphoma that was distributed in a pattern similar to that of liver cancer \[[@B37], [@B38]\].

Among females, the pattern in Lower, Middle, and Upper Egypt was dominated by the high frequency of breast cancer (33.8%, 26.8% and 38.7% resp.) and liver cancer (16.4%, 8.9% and 5.1% resp.). This pattern of liver cancer was similar to that of males with similar relation to the prevalence of HCV. Other differences in site distribution between the 3 regions will be detailed in a separate publication \[[@B39]\].

The national age standardized incidence rates for all cancers in Egypt, excluding nonmelanoma skin cancer, were 175.9/100,000 for males, 157.0/100,000 for females, and 166.6/100,000 for both sexes. The age-standardized rates were intermediate between the rates of more and less developed countries \[[@B33], [@B40], [@B41]\]. For both sexes, the rates for all cancers excluding nonmelanoma skin cancer were 268.3/100,000 for more developed countries and 147.7/100,000 for less developed countries compared to 166.6/100,000 in Egypt. For males, the age-standardized rates were 308.7/100,000 for more developed countries and 163.0/100,000 for less developed countries compared to 175.9/100,000 in Egypt. The rates of females were 240.6/100,000 in more developed countries and 135.8/100,000 in less developed countries compared to 157.0/100,000 for Egypt.

The model used in our study revealed the seriousness of the liver cancer that ranked first among cancers in males (33.6%) and next to breast cancer. Among females the proportion of breast cancer was 32.0% followed by liver cancer (13.5%). The high prevalence of HCV especially genotype IV would explain this high incidence \[[@B34], [@B35]\]. The age-standardized rates for liver cancer for both genders were 5.4/100,000 in more developed countries, 12.0/100,000 in less developed countries compared to 43.6/100,000 in Egypt. Among males the rates were 8.6/100,000 in more developed countries, 17.8/100,000 in less developed countries compared to 61.8/100,000 in Egypt. Among females, the rates were 2.7/100,000 (more developed), 6.6/100,000 (less developed), and 24.4/100,000 (Egypt).

Incidence rate of bladder cancer that ranked next to liver cancer in males was also high. The age-standardized rates are 16.9/100,000 (more developed) and 5.3/100,000 (less developed) compared to 21.1/100,000 in Egypt. Breast cancer was the most frequent cancer among females. The age-standardized rates are 74.1/100,000 (more developed), 31.3/100,000 (less developed), and 48.8/100,000 (Egypt). Analysis of individual sites of cancers will be detailed in a separate publication \[[@B39]\].

Applying the model over successive years for the projected populations showed an increase in number of incident cases from approximately 115,000 patients in 2013 to more than 331,000 in 2050, almost 3-fold increase. The fraction of increase due to population growth gradually decreased over the years with a corresponding increase in the fraction due to demographic transition with ageing of the population. The cancer problem in Egypt would thus be expected to continue simply due to the inevitable ageing of the population with better standards of health care ([Table 10](#tab10){ref-type="table"}).

Rates estimated by the model developed for the study were based on certain assumptions that should be considered in interpretation of results. These assumptions were: (a) constant age-specific rates during the study period; (b) populations of Greater Cairo and Alexandria would be considered a mosaic of the 3 registration regions and would affect the number of incident cases, and not rates; and (c) exclusion of frontier governorates (3.3% of total population of Egypt) that need special studies to get reliable cancer statistics.

5. Conclusion {#sec5}
=============

These results are the first ever published incidence rates for Egypt on a national and regional level and clearly demonstrated the seriousness of the cancer problem of Egypt with age-adjusted incidence rates approaching those of the more developed countries. Liver cancer is a serious if not the most serious cancer problem in Egypt. Nonetheless, these rates should be carefully interpreted being based on a short initial phase of registration and a mathematical model that used regional incidence rates.

The authors acknowledge the important role played by staff of the Ministry of Communication and Information technology specially Dr. Hesham El Deeb engineers El-Sayed Abdelwahid and Mohamed Hamid who were actively behind success of the registry. The dedication of data managers who supervised peripheral registries\' activities during the initial phase of registration, namely, Drs. Amir Bishara (Aswan), Hassan Afifi (Minya), Tarek Heikal (Damietta), and Professor Nelly Alieldin (National Cancer Institute, Cairo University) is also acknowledged. Furthermore, this work would have not been accomplished without the remarkable effort of abstractors, coders, and supporting staff in participating registries.

Statistical Formulas Used in the Analysis {#secA}
=========================================

Step 1 (calculation of regional and national incident cases for census year 2006/sex).(1) Number of incident cancer cases *C* in age group *x*/region *i* where *r* is incidence rate and *w* is population size: $$\begin{matrix}
{C_{xi} = r_{xig}\ast w_{xig}.} \\
\end{matrix}$$(2) Total incident cases in region *i*: *C* ~*i*~ = ∑*C* ~*xi*~.(3) Total incident cases in the 3 regions *G*: *C* ~*G*~ = ∑*C* ~*i*~ where *I* = 1--3.(4) Incident cases in total Egypt *M*: $$\begin{matrix}
{C_{M} = {\sum C_{G}}\ast\left( W_{M}/W_{G} \right)\,\text{where}\,\, W\,\,\text{is}\,\, 2006\,\,\text{population}.} \\
\end{matrix}$$(5) Calculation of national age specific incidence rates *r* ~*xM*~ = ∑*C* ~*xi*~/*W* ~*xi*~ for the 3 regions.

Step 2 (calculation of regional and national incident cases for a given year/sex).The same procedure was followed applying *r* ~*xM*~ calculated above to the population of the year under study.

Step 3 (future projections).For estimation of incident cancer in a specific year till 2050, the national age specific incidence rates by sex were applied to the corresponding population structure \[[@B42]\]. This estimated number would be due to population growth and demographic change with aging of the population. The fraction due to population growth could be calculated using corresponding population sizes. The remainder of increase in number would be due mainly to demographic change.

ASIR:

:   Age specific incidence rate

ASR:

:   Age standardized rate

DCO:

:   Death certificate only

HCV:

:   Hepatitis C virus

IARC:

:   International Agency for Research on Cancer

ICD-10:

:   International Statistical Classification of Diseases and related health problems, 10th revision

NCRP:

:   National Cancer Registry Program of Egypt

NHL:

:   Non-Hodgkin Lymphoma

SEER:

:   Surveillance, Epidemiology, and End Results Program.
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###### 

Population parameters of the 3 regions of Egypt and corresponding registries used in the current report to calculate regional and national incidence rates.

  Region characteristics   Upper Egypt   Middle Egypt   Lower Egypt
  ------------------------ ------------- -------------- -------------
  Regional Registry        Aswan         Minia          Damietta
  Registration period      2008          2009           2009--2011
  Registry Population      1,074,131     4,426,528      3,586,056∗∗
  Region population∗       4,645,449     16,161,200     30,342,291

\*Based upon 2006 census.

\*\*Person years during the registration period.

###### 

Incidence rates of Cancer in Egypt (/100,000 populations) classified by region and sex for all cancer sites with and without nonmelanoma skin cancer (C44).

                                                      Males            Females          All              Male : female ratio                                      
  --------------------------------------------------- ---------------- ---------------- ---------------- --------------------- ---------------- ------- --------- ---------
  All sites                                                                                                                                                        
  \(i\) Upper Egypt                                   97.1             142.8            116.9            167.1                 107.0            155.0   0.8 : 1   0.9 : 1
  (89.1--105.8)                                       (133.1--153.2)   (108.1--126.5)   (156.5--178.4)   (101.0--113.3)        (147.7--162.6)                     
  \(ii\) Middle Egypt                                 109.7            170.0            95.9             132.1                 102.9            151.1   1.1 : 1   1.3 : 1
  (105.4--114.1)                                      (164.7--175.5)   (91.1--100.2)    (127.4--137.0)   (100.0--106.0)        (147.5--154.8)                     
  \(iii\) Lower Egypt                                 138.5            191.8            131.7            173.3                 135.2            182.6   1.1 : 1   1.1 : 1
  (133.2--144.0)                                      (185.6--198.2)   (126.5--137.2)   (167.3--179.6)   (131.4--139.1)        (178.2--187.1)                     
  \(iv\) Calculated rates of Egypt                    117.3            178.5            111.7            159.1                 114.5            169.0   1.1 : 1   1.1 : 1
  (116.0--118.6)                                      (176.9--180.2)   (110.4--113.0)   (157.6--160.7)   (113.6--115.5)        (167.9--170.2)                     
                                                                                                                                                                  
  All sites (excluding nonmelanoma skin cancer C44)                                                                                                                
  \(i\) Upper Egypt                                   96.0             141.0            115.1            163.9                 105.5            152.5   0.8 : 1   0.9 : 1
  (88.1--1104.6)                                      (131.4--151.4)   (106.3--124.5)   (153.4--175.1)   (99.5--111.8)         (145.5--160.1)                     
  \(ii\) Middle Egypt                                 108.0            167.2            94.9             130.7                 101.6            149.0   1.1 : 1   1.3 : 1
  (103.8--112.3)                                      (162.0--172.6)   (90.9--99.1)     (126.0--135.6)   98.7--104.6)          (145.5--152.6)                     
  \(iii\) Lower Egypt                                 136.7            189.1            130.1            170.9                 133.5            180.0   1.1 : 1   1.1 : 1
  (131.5--142.2)                                      (182.9--195.5)   (124.8--135.5)   (164.9--177.1)   (129.7--137.3)        (175.7--184.4)                     
  \(iv\) Calculated rates of Egypt                    115.7            175.9            110.3            157.0                 113.1            166.6   1 : 1     1.1 : 1
  (114.4--117.0)                                      (174.3--177.5)   (109.0--111.6)   (155.4--158.5)   (112.2--114.0)        (165.5--167.8)                     

###### 

Calculated age-specific incidence rates, crude rates, and ASR (World), males, Egypt 2008--2011.

  Site                         0--4   5--9   10--14   15--19   20--24   25--29   30--34   35--39   40--44   45--49   50--54   55--59   60--64   65--69   70--74   75+      Crude rate   ASR     \%
  ---------------------------- ------ ------ -------- -------- -------- -------- -------- -------- -------- -------- -------- -------- -------- -------- -------- -------- ------------ ------- ---------
  Lip                          ---    ---    ---      ---      ---      ---      0.5      ---      0.3      ---      0.8      1.4      0.6      1.8      8.7      1.5      0.3          0.4     0.23%
  Tongue                       ---    ---    ---      ---      ---      ---      ---      ---      0.3      1.4      1.3      3.1      1.9      1.8      ---      2.2      0.3          0.5     0.27%
  Mouth                        ---    ---    ---      0.1      ---      ---      0.2      0.5      0.8      1.5      2.5      4.6      0.6      2.6      1.4      ---      0.5          0.6     0.41%
  Salivary glands              ---    ---    0.1      ---      0.1      ---      ---      0.2      ---      ---      0.7      1.4      2.0      2.6      4.5      5.2      0.3          0.5     0.25%
  Tonsil                       ---    ---    ---      ---      ---      ---      ---      ---      0.3      ---      ---      ---      ---      ---      ---      ---      ---          ---     0.01%
  Other oropharynx             ---    ---    ---      ---      0.1      ---      ---      ---      ---      ---      0.4      0.6      ---      0.8      2.8      ---      0.1          0.1     0.07%
  Nasopharynx                  ---    ---    ---      ---      0.3      ---      ---      0.2      ---      ---      3.4      0.4      ---      3.6      ---      5.2      0.3          0.4     0.26%
  Hypopharynx                  ---    ---    ---      0.1      ---      ---      ---      ---      0.3      ---      0.9      1.4      0.6      ---      1.4      1.5      0.2          0.2     0.13%
  Pharynx unspec.              ---    ---    ---      ---      ---      ---      0.2      ---      ---      1.0      ---      ---      ---      ---      ---      1.5      0.1          0.1     0.07%
  Esophagus                    ---    ---    ---      ---      0.3      0.2      0.3      ---      1.4      1.8      6.1      4.1      11.2     10.8     24.4     14.7     1.4          2.3     1.20%
  Stomach                      ---    0.1    0.1      ---      0.3      0.2      0.7      0.5      2.0      2.6      5.0      6.0      11.9     6.4      21.5     14.1     1.5          2.3     1.26%
  Small intestine              0.1    ---    ---      ---      ---      ---      0.5      0.5      0.6      0.3      0.4      1.4      ---      0.8      ---      1.5      0.2          0.3     0.17%
  Colon                        ---    ---    ---      0.1      0.3      0.7      2.1      2.5      1.9      6.5      14.2     11.0     19.8     18.9     31.5     32.6     3.1          4.7     2.63%
  Rectum                       ---    ---    ---      0.1      0.7      1.2      0.7      1.2      2.2      2.0      3.4      4.1      3.4      2.6      8.7      1.5      1.0          1.3     0.84%
  Anus                         ---    ---    ---      ---      0.3      ---      0.5      0.5      0.6      0.6      ---      2.1      2.0      1.0      ---      ---      0.3          0.3     0.24%
  Liver                        0.3    0.4    0.4      0.2      0.3      1.3      1.4      6.1      21.2     76.3     174.2    258.7    323.1    313.8    327.1    363.5    39.5         61.8    33.63%
  Gallbladder and so forth     ---    ---    ---      ---      ---      0.4      ---      0.5      0.6      0.6      1.0      1.0      5.9      1.0      4.7      7.4      0.5          0.7     0.40%
  Pancreas                     ---    ---    ---      ---      ---      ---      1.3      0.2      2.5      7.7      9.0      14.9     25.3     26.4     12.7     19.3     2.7          4.2     2.31%
  Nose, sinuses and so forth   ---    0.1    ---      ---      ---      ---      ---      0.5      0.3      ---      1.2      ---      ---      ---      1.4      8.2      0.2          0.3     0.17%
  Larynx                       ---    ---    ---      ---      ---      ---      0.2      ---      2.1      2.6      6.6      6.8      18.2     11.0     23.2     32.5     1.9          3.1     1.58%
  Trachea, Bronchus, Lung      0.1    ---    0.1      0.4      0.8      1.2      1.2      3.0      3.8      12.5     19.3     39.1     49.0     49.3     73.9     76.1     6.7          10.4    5.69%
  Other Thoracic organs        0.3    ---    ---      0.1      0.2      0.2      ---      ---      0.6      1.2      2.8      3.5      3.2      7.1      9.8      8.9      0.8          1.2     0.65%
  Bone                         0.1    1.2    1.4      0.7      1.8      0.8      1.0      1.0      1.4      2.0      4.2      3.7      13.9     8.6      8.4      15.6     1.9          2.5     1.62%
  Melanoma of skin             ---    ---    ---      ---      0.1      0.2      ---      ---      0.6      ---      ---      0.4      ---      1.8      2.8      ---      0.1          0.2     0.11%
  Other skin                   0.6    ---    0.1      ---      0.3      0.4      0.5      0.5      1.1      0.6      3.2      4.5      14.0     14.2     18.5     30.4     1.6          2.6     1.35%
  Mesothelioma                 ---    ---    ---      ---      ---      ---      ---      ---      ---      0.8      0.5      1.4      ---      0.8      ---      ---      0.1          0.2     0.10%
  Kaposi sarcoma               ---    ---    ---      ---      ---      ---      0.2      ---      ---      ---      1.1      ---      1.3      0.8      1.4      ---      0.1          0.2     0.10%
  Connective, Soft tissue      0.3    0.1    0.1      0.6      1.1      2.0      1.3      1.3      3.1      3.5      3.6      8.3      4.6      6.1      18.8     2.2      1.7          2.2     1.47%
  Breast                       ---    ---    ---      ---      ---      0.4      ---      0.3      2.2      0.3      2.5      3.1      3.4      3.6      2.8      5.9      0.6          0.9     0.51%
  Penis                        ---    ---    ---      ---      ---      ---      ---      ---      ---      ---      ---      ---      ---      ---      ---      ---      ---          ---     0.00%
  Prostate                     ---    ---    ---      ---      ---      0.2      0.3      ---      0.3      1.3      4.1      11.2     24.6     47.5     90.3     216.5    5.0          9.3     4.27%
  Testis                       ---    0.1    ---      ---      1.1      1.2      0.7      1.5      0.6      0.6      0.4      0.4      0.6      ---      1.4      2.2      0.5          0.5     0.43%
  Other male genital           ---    ---    ---      ---      ---      ---      ---      ---      ---      ---      0.4      ---      ---      0.8      1.4      ---      ---          0.1     0.04%
  Kidney                       1.2    0.1    ---      ---      ---      0.2      0.2      0.5      0.5      3.4      6.9      9.8      7.9      16.9     14.1     22.3     1.8          2.7     1.53%
  Renal pelvis                 ---    ---    ---      ---      0.1      ---      ---      0.2      0.6      0.3      0.4      1.9      2.0      1.8      2.8      4.4      0.3          0.4     0.25%
  Ureter                       ---    ---    ---      ---      ---      ---      ---      ---      ---      ---      ---      ---      ---      ---      1.4      3.0      ---          0.1     0.04%
  Bladder                      0.1    0.1    ---      0.3      0.1      1.2      1.7      2.2      4.0      9.2      28.7     68.4     97.2     128.6    194.8    205.6    12.6         21.1    10.71%
  Other urinary organs         ---    ---    ---      ---      ---      ---      ---      ---      ---      ---      ---      ---      0.6      ---      ---      ---      ---          ---     0.01%
  Eye                          0.5    0.3    ---      ---      ---      ---      ---      ---      ---      0.4      0.4      1.8      0.6      ---      ---      ---      0.2          0.2     0.16%
  Brain, Nervous tissue        2.9    3.0    1.8      1.7      1.5      3.3      4.2      6.8      7.3      7.3      15.5     14.5     27.2     30.4     46.7     91.4     6.4          9.0     5.48%
  Thyroid                      ---    ---    ---      ---      0.2      0.8      1.2      1.9      1.1      3.2      4.5      4.3      6.6      8.7      3.0      ---      1.1          1.5     0.95%
  Adrenal gland                0.3    0.1    ---      ---      ---      ---      ---      ---      ---      ---      ---      0.6      ---      0.8      1.4      ---      0.1          0.1     0.08%
  Other endocrine              0.5    ---    0.1      ---      0.3      ---      ---      0.5      0.3      1.0      0.4      1.3      0.6      ---      2.8      ---      0.3          0.4     0.25%
  Hodgkin disease              0.5    1.7    1.7      1.5      1.5      1.4      ---      0.2      1.7      2.5      2.0      1.4      5.3      6.1      2.8      1.5      1.5          1.7     1.29%
  Non-Hodgkin lymphoma         1.1    1.2    1.5      1.0      2.2      2.5      2.1      3.6      5.8      16.6     24.4     36.0     33.8     29.5     38.1     28.8     6.4          8.8     5.48%
  Immunoproliferative dis.     ---    ---    ---      ---      ---      ---      ---      ---      ---      ---      ---      ---      ---      ---      ---      ---      ---          ---     0.00%
  Multiple myeloma             ---    ---    ---      ---      ---      ---      0.5      0.5      1.1      0.4      3.1      3.9      8.0      0.8      2.8      2.9      0.6          0.9     0.53%
  Lymphoid leukemia            3.9    2.2    0.7      0.2      1.4      ---      0.7      1.5      1.1      1.8      1.5      5.0      6.0      8.9      5.6      ---      1.8          2.1     1.50%
  Myeloid Leukemia             0.8    0.4    0.3      0.8      1.0      0.4      1.1      0.7      1.4      1.8      4.2      3.3      3.4      2.6      4.5      1.5      1.1          1.3     0.96%
  Leukemia unspec.             1.0    1.2    1.1      0.6      2.1      2.2      1.7      0.5      2.1      4.7      1.8      6.0      8.0      3.5      7.3      20.8     2.1          2.6     1.80%
  Other & unspecified          2.4    2.8    0.9      1.7      1.3      1.8      3.3      3.1      6.1      15.0     22.9     25.2     44.9     54.7     64.7     83.6     7.6          11.2    6.52%
                                                                                                                                                                                                
  All sites Total              17.1   15.4   10.5     10.5     20.1     23.9     30.6     42.8     83.8     195.4    389.6    582.4    793.5    840.2    1096.1   1335.6   117.3        178.5   100.00%
  All sites but C44^\#^        16.6   15.4   10.4     10.5     19.8     23.5     30.0     42.4     82.7     194.9    386.4    577.9    779.5    826.0    1077.5   1305.3   115.7        175.9   98.65%

^\#^Incidence rates do not include nonmelanoma skin cancer.

###### 

Calculated age-specific incidence rates, crude rates, and ASR (World), females, Egypt 2008--2011.

  Site                         0--4   5--9   10--14   15--19   20--24   25--29   30--34   35--39   40--44   45--49   50--54   55--59   60--64   65--69   70--74   75+     Crude rate   ASR     \%
  ---------------------------- ------ ------ -------- -------- -------- -------- -------- -------- -------- -------- -------- -------- -------- -------- -------- ------- ------------ ------- ---------
  Lip                          ---    ---    ---      ---      ---      ---      ---      ---      0.3      1.4      0.8      0.5      1.6      0.8      1.3      4.7     0.2          0.4     0.21%
  Tongue                       ---    ---    ---      ---      ---      0.5      ---      ---      ---      0.4      0.4      1.2      0.7      ---      ---      15.4    0.3          0.5     0.26%
  Mouth                        ---    0.1    0.1      ---      ---      ---      ---      ---      0.3      1.0      0.8      0.5      1.4      2.9      6.1      2.7     0.3          0.5     0.28%
  Salivary glands              ---    ---    0.3      ---      ---      ---      ---      ---      ---      0.7      ---      2.9      0.7      2.9      ---      ---     0.2          0.3     0.18%
  Tonsil                       ---    ---    ---      ---      ---      ---      ---      ---      ---      ---      ---      ---      ---      2.2      ---      1.4     ---          0.1     0.04%
  Other oropharynx             ---    ---    ---      ---      ---      ---      ---      ---      ---      0.3      ---      0.7      ---      0.8      ---      ---     ---          0.1     0.04%
  Nasopharynx                  0.1    ---    0.1      ---      ---      ---      ---      ---      ---      ---      ---      ---      1.6      ---      ---      ---     0.1          0.1     0.06%
  Hypopharynx                  ---    ---    ---      ---      ---      0.2      ---      0.4      0.3      1.0      0.9      0.5      ---      1.1      ---      ---     0.2          0.2     0.16%
  Pharynx unspec.              ---    ---    ---      ---      ---      0.2      ---      ---      ---      ---      ---      ---      ---      ---      ---      ---     ---          ---     0.01%
  Esophagus                    ---    ---    ---      ---      ---      0.2      ---      ---      2.0      1.3      0.8      3.7      11.1     10.6     9.2      5.4     0.9          1.5     0.79%
  Stomach                      ---    0.1    ---      ---      ---      ---      2.0      1.4      3.1      5.1      5.7      5.1      9.7      16.3     18.7     14.8    1.8          2.7     1.65%
  Small intestine              ---    ---    ---      ---      ---      ---      ---      0.4      ---      1.9      1.7      ---      1.4      5.2      4.8      ---     0.4          0.5     0.32%
  Colon                        ---    ---    ---      ---      0.5      0.5      1.0      2.4      2.9      7.9      9.4      7.9      10.4     25.2     16.2     29.4    2.5          3.8     2.28%
  Rectum                       ---    ---    ---      ---      0.1      1.1      1.2      0.7      1.9      1.7      1.9      2.9      3.0      3.9      4.4      5.4     0.8          1.1     0.72%
  Anus                         ---    ---    ---      ---      ---      0.2      ---      ---      0.3      ---      0.5      ---      1.6      ---      1.3      ---     0.1          0.1     0.09%
  Liver                        1.0    ---    0.5      ---      ---      0.9      2.0      3.3      12.5     25.2     43.2     89.3     129.3    143.9    167.9    150.4   15.1         24.4    13.54%
  Gallbladder and so forth     ---    ---    ---      ---      0.3      ---      0.5      0.5      0.3      1.3      2.5      3.3      2.2      3.7      6.9      6.0     0.6          0.9     0.55%
  Pancreas                     ---    ---    ---      ---      ---      0.4      ---      0.5      0.6      3.0      3.4      8.6      9.0      18.7     24.4     19.5    1.6          2.6     1.41%
  Nose, sinuses and so forth   0.1    ---    ---      ---      ---      ---      ---      ---      0.3      0.7      1.2      1.2      5.4      ---      ---      ---     0.3          0.4     0.23%
  Larynx                       ---    ---    ---      ---      ---      ---      ---      ---      0.3      1.0      2.0      ---      3.0      ---      3.0      2.1     0.3          0.4     0.23%
  Trachea, Bronchus, Lung      0.7    ---    0.1      0.1      0.5      2.0      1.0      1.5      1.7      6.9      12.3     11.7     15.1     11.3     35.9     38.0    3.0          4.5     2.70%
  Other Thoracic organs        ---    ---    ---      ---      ---      ---      ---      ---      0.8      1.7      1.6      2.6      1.6      3.0      1.3      10.7    0.5          0.7     0.42%
  Bone                         0.7    0.1    1.1      2.0      1.4      0.7      0.7      2.2      0.9      2.3      6.5      6.7      12.0     4.5      2.6      16.9    2.0          2.5     1.80%
  Melanoma of skin             ---    ---    ---      ---      ---      ---      ---      ---      0.6      ---      ---      ---      ---      2.2      4.4      ---     0.1          0.2     0.10%
  Other skin                   0.3    ---    ---      0.2      ---      0.4      0.5      ---      2.0      2.7      1.2      8.6      10.4     14.0     14.9     11.8    1.4          2.2     1.24%
  Mesothelioma                 ---    ---    ---      ---      ---      ---      ---      ---      ---      ---      1.2      0.5      3.0      1.1      4.8      ---     0.2          0.3     0.17%
  Kaposi sarcoma               ---    ---    ---      ---      ---      ---      ---      ---      ---      ---      ---      ---      ---      0.8      ---      ---     ---          ---     0.01%
  Connective, Soft tissue      1.2    0.3    0.7      0.4      1.5      2.1      1.7      1.2      2.0      2.0      2.9      2.4      6.2      3.9      3.1      13.4    1.6          1.9     1.42%
  Breast                       ---    ---    ---      ---      3.1      9.5      29.2     49.0     86.0     106.2    136.0    172.9    177.4    166.3    138.7    148.6   35.8         48.8    32.04%
  Vulva                        0.1    ---    0.1      ---      ---      ---      ---      ---      ---      0.3      ---      1.0      ---      0.8      ---      1.4     0.1          0.1     0.09%
  Vagina                       ---    ---    ---      ---      ---      ---      ---      ---      ---      ---      ---      1.0      3.0      3.3      ---      1.4     0.2          0.3     0.14%
  Cervix Uteri                 ---    ---    ---      ---      ---      0.2      0.2      ---      0.6      3.6      6.5      9.1      8.3      10.5     1---     9.4     1.3          2.0     1.17%
  Corpus Uteri                 ---    ---    ---      ---      ---      ---      0.5      0.2      0.6      1.3      0.7      8.1      4.3      3.0      3.0      12.1    0.7          1.1     0.62%
  Uterus unspec.               ---    ---    ---      0.5      1.2      0.4      0.7      0.5      1.8      1.6      11.1     9.5      21.5     20.4     31.4     21.2    2.5          3.9     2.27%
  Ovary                        ---    ---    0.5      0.4      0.8      1.5      1.5      3.3      8.7      17.2     20.3     24.0     19.6     17.2     2---     26.3    4.6          6.3     4.12%
  Other female genital         ---    ---    ---      ---      ---      ---      ---      0.3      ---      ---      ---      ---      ---      ---      1.3      2.1     0.1          0.1     0.05%
  Placenta                     ---    ---    ---      ---      ---      0.4      ---      ---      ---      ---      ---      ---      ---      ---      ---      ---     ---          ---     0.03%
  Kidney                       1.5    0.1    ---      ---      ---      0.5      0.8      0.5      0.6      2.9      2.3      1.0      10.4     10.7     1.3      7.3     1.1          1.6     0.97%
  Renal pelvis                 ---    0.3    ---      ---      ---      0.6      ---      0.2      ---      0.7      0.4      0.5      1.6      0.8      ---      ---     0.2          0.3     0.19%
  Ureter                       ---    ---    ---      ---      ---      ---      ---      ---      ---      ---      ---      ---      ---      ---      ---      ---     ---          ---     0.00%
  Bladder                      0.1    ---    ---      0.2      ---      0.2      ---      0.7      0.8      5.3      8.2      18.6     20.2     37.8     43.6     53.9    3.3          5.5     2.96%
  Other urinary organs         ---    ---    ---      ---      ---      ---      ---      ---      ---      ---      ---      ---      ---      2.2      ---      ---     ---          0.1     0.03%
  Eye                          0.1    0.3    ---      ---      ---      ---      0.5      ---      ---      ---      ---      1.2      0.7      0.8      ---      1.4     0.2          0.2     0.14%
  Brain, Nervous tissue        3.3    2.1    1.9      0.8      2.9      0.7      4.5      6.5      6.6      9.5      11.3     12.1     31.4     26.3     33.1     72.2    5.8          8.0     5.18%
  Thyroid                      ---    ---    ---      ---      2.7      2.8      10.2     7.2      6.4      9.7      10.2     11.0     9.0      2.6      10.4     14.2    3.7          4.3     3.28%
  Adrenal gland                1.5    0.1    ---      ---      ---      ---      ---      ---      ---      ---      ---      1.2      ---      ---      ---      1.4     0.2          0.3     0.20%
  Other endocrine              ---    0.1    ---      0.1      0.1      0.3      ---      0.5      0.3      0.3      0.4      1.0      0.7      0.8      ---      ---     0.2          0.2     0.19%
  Hodgkin disease              ---    0.6    0.4      1.9      1.3      0.4      1.2      0.7      0.6      0.4      ---      1.2      3.8      ---      ---      ---     0.8          0.8     0.70%
  Non-Hodgkin lymphoma         0.9    0.7    ---      1.1      0.8      1.2      1.7      3.3      3.8      8.6      16.0     23.4     24.1     16.8     31.3     36.7    4.2          6.1     3.80%
  Immunoproliferative dis.     ---    ---    ---      ---      ---      ---      ---      ---      ---      ---      ---      ---      ---      ---      ---      ---     ---          ---     0.00%
  Multiple myeloma             ---    ---    ---      ---      ---      ---      ---      ---      0.6      1.4      0.8      1.2      2.3      4.4      6.1      2.7     0.4          0.6     0.34%
  Lymphoid leukemia            2.0    0.7    0.9      0.4      0.5      ---      0.7      0.7      1.4      1.0      2.7      1.7      2.8      3.9      4.4      ---     1.0          1.2     0.93%
  Myeloid Leukemia             0.5    0.3    0.7      0.2      1.5      1.5      1.4      1.0      0.9      0.7      4.0      3.1      6.8      7.5      ---      4.9     1.3          1.6     1.14%
  Leukemia unspec.             0.4    0.7    0.7      1.3      0.9      1.7      1.5      0.7      1.4      2.7      3.3      5.5      6.1      8.3      7.4      14.8    1.7          2.2     1.55%
  Other & unspecified          1.4    0.9    1.9      1.7      2.4      3.9      4.6      5.5      9.6      12.5     23.8     37.3     39.9     42.1     42.6     70.5    7.7          10.8    6.93%
                                                                                                                                                                                               
  All sites Total              16.1   7.8    10.1     11.4     22.4     34.9     69.7     95.2     163.7    255.3    359.1    506.5    633.7    665.8    715.9    850.5   111.7        159.1   100.00%
  All sites but C44^\#^        15.8   7.8    10.1     11.2     22.4     34.6     69.3     95.2     161.6    252.5    357.9    497.8    623.3    651.8    701.0    838.7   110.3        157.0   98.76%

^\#^Incidence rates do not include nonmelanoma skin cancer.

###### 

The most frequent cancers in Egypt estimated using the results of the National Population-Based Registry Program of Egypt 2008--2011.

                         Site     \%      Crude rate   ASR
  ---------------------- -------- ------- ------------ ------
  Males                  Liver    33.63   39.5         61.8
  Bladder                10.71    12.6    21.1         
  Lung^\#^               5.69     6.7     10.4         
  Non-Hodgkin lymphoma   5.48     6.4     8.8          
  Brain^\#\#^            5.48     6.4     8.8          
  Prostate               4.27     5.0     9.3          
                                                       
  Females                Breast   32.04   35.8         48.8
  Liver                  13.54    15.1    24.4         
  Brain^\#\#^            5.18     5.8     8.0          
  Ovary                  4.12     4.6     6.3          
  Non-Hodgkin lymphoma   3.80     4.2     6.1          
  Thyroid                3.28     3.7     4.3          
                                                       
  Both Sexes             Liver    23.81   27.5         43.6
  Breast                 15.41    17.8    24.3         
  Bladder                6.94     8.0     13.5         
  Brain^\#\#^            5.29     6.1     8.5          
  Non-Hodgkin lymphoma   4.64     5.4     7.5          
  Lung^\#^               4.22     4.9     7.5          

^\#^Includes trachea, bronchus, and lung tumors.

^\#\#^Includes brain and nervous system tumors.

###### 

Incidence rates/100,000 population of individual cancer sites in Lower, Middle, and Upper Egypt: males.

  Primary site                 Lower Egypt   Middle Egypt   Upper Egypt                                            
  ---------------------------- ------------- -------------- ------------- ------- ------- --------- ------ ------- ---------
  Lip                          0.4           0.4            0.28%         0.3     0.5     0.24%     0.4    0.6     0.38%
  Tongue                       0.3           0.3            0.20%         0.2     0.4     0.20%     1.1    1.5     1.15%
  Mouth                        0.2           0.3            0.16%         0.8     1.1     0.73%     1.3    1.9     1.34%
  Salivary glands              0.3           0.4            0.20%         0.4     0.5     0.36%     0.6    0.9     0.57%
  Tonsil                       0.0           0.0            0.00%         0.0     0.1     0.04%     0.0    0.0     0.00%
  Other oropharynx             0.0           0.0            0.00%         0.2     0.3     0.20%     0.2    0.3     0.19%
  Nasopharynx                  0.5           0.5            0.35%         0.1     0.1     0.12%     0.6    1.0     0.57%
  Hypopharynx                  0.0           0.0            0.00%         0.3     0.5     0.28%     0.6    0.9     0.57%
  Pharynx unspec.              0.1           0.1            0.04%         0.1     0.1     0.08%     0.2    0.3     0.19%
  Esophagus                    1.0           1.3            0.71%         1.8     3.0     1.61%     3.9    5.5     4.01%
  Stomach                      1.4           2.0            0.98%         1.7     2.5     1.53%     2.4    3.8     2.48%
  Small intestine              0.1           0.1            0.04%         0.5     0.6     0.44%     0.2    0.2     0.19%
  Colon                        4.0           5.4            2.91%         2.3     3.7     2.10%     2.4    3.7     2.48%
  Rectum                       0.9           1.1            0.67%         1.2     1.6     1.13%     0.7    1.1     0.76%
  Anus                         0.4           0.4            0.28%         0.2     0.2     0.16%     0.4    0.5     0.38%
  Liver                        57.8          81             41.71%        22.4    37.6    20.42%    11.5   17.5    11.83%
  Gallbladder and so forth     0.5           0.5            0.39%         0.4     0.7     0.32%     1.3    2.2     1.34%
  Pancreas                     3.2           4.4            2.28%         2.1     3.5     1.94%     3.5    5.4     3.63%
  Nose, sinuses and so forth   0.1           0.1            0.04%         0.4     0.6     0.32%     0.6    0.9     0.57%
  Larynx                       0.8           1.3            0.59%         3.3     5.7     3.03%     3.9    6.0     4.01%
  Trachea, Bronchus, Lung      7.6           10.1           5.47%         6.3     10.8    5.77%     7.4    11.5    7.63%
  Other Thoracic organs        1.0           1.3            0.71%         0.8     1.2     0.69%     0.6    0.8     0.57%
  Bone                         1.9           2.4            1.34%         2.3     3.4     2.10%     1.5    1.9     1.53%
  Melanoma of skin             0.2           0.2            0.12%         0.1     0.1     0.12%     0.0    0.0     0.00%
  Other skin                   1.8           2.7            1.30%         1.7     2.8     1.53%     1.1    1.8     1.15%
  Mesothelioma                 0.0           0.0            0.00%         0.3     0.4     0.24%     0.4    0.6     0.38%
  Kaposi sarcoma               0.1           0.1            0.08%         0.2     0.3     0.16%     0.0    0.0     0.00%
  Connective, Soft tissue      2.5           2.6            1.77%         0.5     0.8     0.48%     3.0    3.8     3.05%
  Breast                       0.7           0.8            0.47%         0.4     0.6     0.32%     1.1    1.8     1.15%
  Penis                        0.0           0.0            0.00%         0.0     0.0     0.00%     0.0    0.0     0.00%
  Prostate                     6.7           11.7           4.84%         2.9     5.2     2.66%     5.7    9.2     5.92%
  Testis                       0.5           0.4            0.35%         0.5     0.7     0.48%     0.4    0.5     0.38%
  Other male genital           0.0           0.0            0.00%         0.1     0.2     0.12%     0.0    0.0     0.00%
  Kidney                       2.2           3.2            1.61%         1.7     2.5     1.53%     0.9    1.3     0.95%
  Renal pelvis                 0.2           0.3            0.12%         0.5     0.8     0.48%     0.4    0.5     0.38%
  Ureter                       0.1           0.1            0.04%         0.0     0.1     0.04%     0.0    0.0     0.00%
  Bladder                      12.2          19             8.82%         15.6    26.4    14.25%    12.2   19.3    12.60%
  Other urinary organs         0.0           0.0            0.00%         0.0     0.0     0.00%     0.2    0.3     0.19%
  Eye                          0.1           0.2            0.08%         0.3     0.4     0.24%     0.7    0.6     0.76%
  Brain, Nervous tissue        6.2           8.1            4.49%         8.0     12.5    7.26%     5.2    6.7     5.34%
  Thyroid                      1.3           1.5            0.91%         1.2     1.7     1.05%     0.7    1.1     0.76%
  Adrenal gland                0.0           0.0            0.00%         0.1     0.2     0.12%     0.6    0.8     0.57%
  Other endocrine              0.1           0.1            0.08%         0.6     0.8     0.56%     0.4    0.4     0.38%
  Hodgkin disease              1.6           1.8            1.18%         1.7     2.0     1.53%     1.5    1.5     1.53%
  Non-Hodgkin lymphoma         8.3           10.3           6.03%         5.2     7.6     4.76%     2.8    4.2     2.86%
  Immunoproliferative dis.     0.0           0.0            0.00%         0.0     0.0     0.00%     0.0    0.0     0.00%
  Multiple myeloma             0.7           0.9            0.51%         0.7     1.1     0.61%     0.2    0.3     0.19%
  Lymphoid leukemia            1.7           2.2            1.22%         1.8     2.3     1.61%     3.0    3.1     3.05%
  Myeloid Leukemia             0.9           1.0            0.63%         1.6     1.8     1.45%     1.9    2.5     1.91%
  Leukemia unspec.             2.4           3.1            1.73%         2.0     2.6     1.86%     1.1    1.1     1.15%
  Other & unspecified          5.9           8.3            4.25%         13.9    17.6    12.67%    8.7    13      8.97%
                                                                                                                   
  All sites Total              138.5         191.8          100.00%       109.7   170     100.00%   97.1   142.8   100.00%
  All sites but C44^\#^        136.7         189.1          98.70%        108     167.2   98.47%    96     141     98.85%

^\#^Incidence rates do not include nonmelanoma skin cancer.

###### 

Incidence rates/100,000 population of individual cancer sites in Lower, Middle, and Upper Egypt: females.

  Primary site                 Lower Egypt   Middle Egypt   Upper Egypt                                            
  ---------------------------- ------------- -------------- ------------- ------ ------- --------- ------- ------- ---------
  Lip                          0.3           0.4            0.26%         0.2    0.4     0.24%     0.0     0.0     0.00%
  Tongue                       0.3           0.5            0.26%         0.3    0.5     0.34%     0.2     0.2     0.16%
  Mouth                        0.1           0.2            0.09%         0.5    0.8     0.53%     0.9     1.5     0.80%
  Salivary glands              0.2           0.2            0.13%         0.3    0.4     0.29%     0.2     0.4     0.16%
  Tonsil                       0.1           0.1            0.04%         0.0    0.1     0.05%     0.0     0.0     0.00%
  Other oropharynx             0.0           0.0            0.00%         0.1    0.1     0.10%     0.2     0.3     0.16%
  Nasopharynx                  0.1           0.1            0.04%         0.0    0       0.05%     0.2     0.2     0.16%
  Hypopharynx                  0.0           0.0            0.00%         0.4    0.4     0.38%     0.6     0.9     0.48%
  Pharynx unspec.              0.0           0.0            0.00%         0.0    0.0     0.05%     0.0     0.0     0.00%
  Esophagus                    0.9           1.2            0.65%         1.2    1.9     1.25%     1.1     1.6     0.96%
  Stomach                      2.3           3.2            1.73%         1.2    1.8     1.25%     1.9     3.1     1.60%
  Small intestine              0.3           0.5            0.22%         0.4    0.6     0.43%     0.6     0.9     0.48%
  Colon                        3.0           4.2            2.30%         2.2    3.2     2.31%     2.4     3.5     2.08%
  Rectum                       0.9           1.0            0.65%         1.0    1.2     1.01%     0.7     1.3     0.64%
  Anus                         0.1           0.1            0.04%         0.1    0.2     0.14%     0.2     0.3     0.16%
  Liver                        21.6          32.6           16.37%        8.6    13.7    8.95%     6.0     8.7     5.12%
  Gallbladder and so forth     0.5           0.5            0.35%         0.6    0.9     0.58%     1.9     3.1     1.60%
  Pancreas                     2.1           3.2            1.60%         0.9    1.4     0.91%     1.7     2.3     1.44%
  Nose, sinuses and so forth   0.3           0.5            0.26%         0.1    0.2     0.14%     0.2     0.2     0.16%
  Larynx                       0.2           0.3            0.17%         0.3    0.4     0.29%     0.4     0.7     0.32%
  Trachea, Bronchus, Lung      3.7           5.3            2.82%         2.2    3.1     2.26%     2.4     3.8     2.08%
  Other Thoracic organs        0.6           0.8            0.43%         0.5    0.7     0.48%     0.0     0.0     0.00%
  Bone                         2.0           2.3            1.52%         1.8    2.4     1.92%     3.4     4.4     2.88%
  Melanoma of skin             0.2           0.3            0.17%         0.0    0.1     0.05%     0.0     0.0     0.00%
  Other skin                   1.7           2.4            1.26%         1.0    1.5     1.06%     1.9     3.1     1.60%
  Mesothelioma                 0.3           0.3            0.22%         0.2    0.3     0.24%     0.4     0.7     0.32%
  Kaposi sarcoma               0.0           0.0            0.00%         0.0    0.1     0.05%     0.0     0.0     0.00%
  Connective, Soft tissue      2.3           2.6            1.78%         0.4    0.6     0.38%     1.9     2.2     1.60%
  Breast                       43.8          53             33.22%        25.8   35.6    26.84%    45.3    64.5    38.72%
  Vulva                        0.0           0.0            0.00%         0.3    0.4     0.34%     0.0     0.0     0.00%
  Vagina                       0.1           0.2            0.09%         0.1    0.2     0.14%     0.6     1.0     0.48%
  Cervix Uteri                 1.7           2.4            1.26%         1.0    1.5     1.06%     0.6     0.9     0.48%
  Corpus Uteri                 0.6           0.9            0.43%         0.6    0.9     0.67%     1.7     2.9     1.44%
  Uterus unspec.               3.7           5.3            2.77%         1.0    1.3     1.06%     2.4     3.8     2.08%
  Ovary                        5.1           6.4            3.90%         3.6    5.0     3.75%     7.1     10.2    6.08%
  Other female genital         0.0           0.0            0.00%         0.0    0.1     0.05%     0.4     0.6     0.32%
  Placenta                     0.0           0.0            0.00%         0.0    0.0     0.05%     0.2     0.2     0.16%
  Kidney                       1.1           1.6            0.87%         1.2    1.8     1.25%     0.7     1.1     0.64%
  Renal pelvis                 0.2           0.3            0.17%         0.2    0.3     0.19%     0.2     0.2     0.16%
  Ureter                       0.0           0.0            0.00%         0.0    0.0     0.00%     0.0     0.0     0.00%
  Bladder                      3.7           5.9            2.77%         3.1    4.9     3.27%     3.6     5.7     3.04%
  Other urinary organs         0.1           0.1            0.04%         0.0    0.0     0.00%     0.0     0.0     0.00%
  Eye                          0.1           0.1            0.04%         0.3    0.5     0.34%     0.2     0.2     0.16%
  Brain, Nervous tissue        5.8           7.4            4.42%         7.4    11.1    7.70%     2.4     2.9     2.08%
  Thyroid                      5.1           5.4            3.90%         1.6    2.1     1.64%     3.6     4.2     3.04%
  Adrenal gland                0.2           0.3            0.17%         0.2    0.3     0.24%     0.2     0.2     0.16%
  Other endocrine              0.1           0.0            0.04%         0.5    0.7     0.53%     0.2     0.2     0.16%
  Hodgkin disease              1.0           0.7            0.74%         1.0    1.0     1.01%     0.9     0.9     0.80%
  Non-Hodgkin lymphoma         5.4           6.7            4.11%         4.2    5.8     4.43%     2.6     3.8     2.24%
  Immunoproliferative dis.     0.0           0.0            0.00%         0.0    0.0     0.00%     0.0     0.0     0.00%
  Multiple myeloma             0.7           0.9            0.52%         0.1    0.3     0.14%     0.2     0.0     0.16%
  Lymphoid leukemia            1.0           1.1            0.74%         1.2    1.6     1.25%     1.5     1.6     1.28%
  Myeloid Leukemia             0.9           1.1            0.65%         1.7    2.0     1.78%     2.2     3.3     1.92%
  Leukemia unspec.             1.8           2.4            1.34%         1.6    2.0     1.68%     1.9     2.3     1.60%
  Other & unspecified          5.9           8.2            4.46%         14.3   15.5    14.86%    9.2     12.9    7.84%
                                                                                                                   
  All sites Total              131.7         173.3          100.00%       95.9   132.1   100.00%   116.9   167.1   100.00%
  All sites but C44^\#^        130.1         170.9          98.74%        94.9   130.7   98.94%    115.1   163.9   98.40%

^\#^Incidence rates do not include nonmelanoma skin cancer.

###### 

Proportions and incidence rates of the most frequently observed cancers in the 3 regions of Egypt.

               Lower Egypt   Middle Egypt   Upper Egypt                                                                            
  ------------ ------------- -------------- ------------- ------------ -------- ------ ------ ------------ --------- ------ ------ ------
  Males        Liver         41.7           57.8          81.0         Liver    20.4   22.4   37.6         Bladder   12.6   12.2   19.3
  Bladder      8.8           12.2           19.0          Bladder      14.2     15.6   26.4   Liver        11.8      11.5   17.5   
  NHL          6.0           8.3            10.3          Brain^\#^    7.3      8.0    12.5   Lung^\#\#^   7.6       7.4    11.5   
  Lung^\#\#^   5.5           7.6            10.1          Lung^\#\#^   5.8      6.3    10.8   Leukemia     6.1       6.0    6.7    
  Prostate     4.8           6.7            11.7          Leukemia     4.9      5.4    6.7    Prostate     5.9       5.7    9.2    
                                                                                                                                   
  Females      Breast        33.2           43.8          53.0         Breast   26.8   25.8   35.6         Breast    38.7   45.3   64.5
  Liver        16.4          21.6           32.6          Liver        8.9      8.6    13.7   Ovary        6.1       7.1    10.2   
  Brain^\#^    4.4           5.8            7.4           Brain^\#^    7.7      7.4    11.1   Liver        5.1       6.0    8.7    
  NHL          4.1           5.4            6.7           Leukemia     4.7      4.5    5.6    Leukemia     4.8       5.6    7.2    
  Thyroid      3.9           5.1            5.4           NHL          4.4      4.2    5.8    Uterus       3.5       4.1    6.7    
                                                                                                                                   
  Both Sexes   Liver         29.6           40.1          56.8         Liver    15.2   15.6   25.7         Breast    21.6   23.1   33.2
  Breast       16.1          21.7           26.9          Breast       12.4     12.8   18.1   Liver        8.2       8.8    13.1   
  Bladder      5.9           8.0            12.5          Bladder      9.2      9.5    15.7   Bladder      7.4       7.9    12.5   
  NHL          5.1           6.9            8.5           Brain^\#^    7.5      7.7    11.8   Leukemia     5.4       5.7    7.0    
  Brain^\#^    4.5           6.0            7.8           Leukemia     4.8      4.9    6.2    Lung^\#\#^   4.6       4.9    7.7    

^\#^Includes brain and nervous system tumors.

^\#\#^Includes trachea, bronchus and lung tumors.

###### 

Estimated number of cancer cases, Egypt 2013--2050.

                               2013    2015    2020     2025    2050                                                                                 
  ---------------------------- ------- ------- -------- ------- ------- -------- ------- ------- -------- ------- ------- -------- -------- -------- --------
  Lip                          135     126     262      146     135     281      178     164     342      206     202     408      438      427      866
  Tongue                       155     175     330      164     185     349      186     231     417      219     296     515      417      763      1180
  Mouth                        228     163     391      243     178     420      275     216     491      314     261     575      544      528      1071
  Salivary glands              147     108     255      158     117     275      189     130     319      222     153     375      495      265      760
  Tonsil                       6       31      37       6       33      40       9       41      50       11      54      65       13       129      142
  Other oropharynx             42      25      67       45      28      73       54      30      85       63      37      100      132      65       198
  Nasopharynx                  145     32      178      154     34      188      171     40      211      207     42      249      428      68       496
  Hypopharynx                  72      80      152      76      85      161      88      96      184      102     111     213      200      173      372
  Pharynx unspec.              35      7       42       36      7       43       42      7       48       55      7       62       94       8        102
  Oesophagus                   699     485     1184     746     525     1271     897     644     1542     1065    762     1827     2249     1504     3752
  Stomach                      726     969     1695     772     1045    1816     922     1249    2171     1080    1484    2565     2185     2877     5062
  Small intestine              98      179     277      106     194     300      120     229     349      134     274     408      223      507      730
  Colon                        1522    1339    2862     1618    1437    3055     1893    1715    3608     2225    2063    4287     4465     4120     8585
  Rectum                       464     406     871      490     432     922      568     502     1070     645     584     1230     1097     1052     2149
  Anus                         133     50      183      142     53      195      162     65      227      178     71      249      291      127      418
  Liver                        19646   8345    27991    20932   9043    29975    24420   10900   35320    28580   12933   41513    59047    26425    85471
  Gallbladder and so forth     235     324     559      248     350     598      297     413     710      348     488     835      715      967      1682
  Pancreas                     1350    876     2226     1440    957     2397     1676    1160    2836     1961    1405    3366     3912     2971     6883
  Nose, sinuses and so forth   98      136     234      104     144     247      124     170     294      154     186     340      340      322      661
  Larynx                       933     134     1067     993     142     1136     1194    173     1367     1428    201     1629     3094     395      3489
  Trachea, Bronchus, Lung      3304    1586    4890     3530    1703    5233     4168    2031    6198     4889    2404    7293     10176    4895     15071
  Other Thoracic organs        368     260     628      393     277     670      464     335     798      551     415     966      1149     897      2046
  Bone                         889     957     1846     935     1011    1946     1068    1174    2242     1216    1330    2546     2212     2401     4613
  Melanoma of skin             60      59      119      66      66      132      82      84      166      95      105     200      181      207      388
  Other skin                   797     749     1547     853     813     1666     1018    973     1990     1205    1160    2365     2641     2306     4947
  Mesothelioma                 55      106     161      58      116     174      65      143     207      76      161     238      135      321      456
  Kaposi sarcoma               60      8       68       63      9       72       72      10      82       81      13      95       159      28       187
  Connective, Soft tissue      801     751     1552     846     787     1633     981     901     1882     1113    1026    2139     1924     1796     3720
  Breast                       287     17905   18192    306     19105   19411    362     22320   22682    422     25793   26215    807      45243    46050
  Vulva                        0       52      52       0       56      56       0       63      63       0       76      76       0        146      146
  Vagina                       0       95      95       0       103     103      0       126     126      0       147     147      0        305      305
  Cervix Uteri                 0       701     701      0       752     752      0       882     882      0       1039    1039     0        2039     2039
  Corpus Uteri                 0       392     392      0       426     426      0       502     502      0       600     600      0        1256     1256
  Uterus unspec.               0       1353    1353     0       1456    1456     0       1758    1758     0       2055    2055     0        4143     4143
  Ovary                        0       2288    2288     0       2434    2434     0       2830    2830     0       3311    3311     0        5957     5957
  Other female genital         0       30      30       0       34      34       0       44      44       0       55      55       0        134      134
  Placenta                     0       14      14       0       14      14       0       14      14       0       15      15       0        18       18
  Penis                        0       0       0        0       0       0        0       0       0        0       0       0        0        0        0
  Prostate                     2544    0       2544     2747    0       2747     3398    0       3398     4295    0       4295     10785    0        10785
  Testis                       229     0       229      240     0       240      266     0       266      291     0       291      425      0        425
  Other male genital           21      0       21       22      0       22       28      0       28       33      0       33       73       0        73
  Kidney                       877     561     1438     934     594     1528     1080    693     1774     1274    801     2076     2628     1487     4115
  Renal pelvis                 141     99      240      152     103     255      183     115     297      214     126     341      446      196      642
  Ureter                       22      0       22       24      0       24       31      0       31       41      0       41       111      0        111
  Bladder                      6362    1872    8234     6852    2038    8891     8228    2481    10709    9746    3016    12762    21783    6554     28337
  Other urinary organs         8       21      29       8       23      31       10      27      37       11      35      46       22       72       94
  Eye                          89      82      171      92      87      180      98      96      194      104     108     212      160      195      355
  Brain, Nervous tissue        3072    2933    6004     3256    3133    6389     3779    3721    7500     4390    4351    8740     8439     8450     16888
  Thyroid                      547     1759    2306     582     1867    2448     661     2106    2767     748     2363    3111     1298     3814     5113
  Adrenal gland                43      105     149      46      109     155      52      113     166      57      121     178      102      180      282
  Other endocrine              129     95      224      136     100     236      156     114     269      174     125     300      273      188      462
  Hodgkin disease              647     321     968      673     336     1008     751     371     1123     837     397     1234     1245     527      1772
  Non-Hodgkin lymphoma         3053    2188    5241     3223    2345    5568     3689    2755    6444     4240    3202    7442     7749     6135     13884
  Immunoproliferative dis.     0       0       0        0       0       0        0       0       0        0       0       0        0        0        0
  Multiple myeloma             316     200     516      334     218     552      386     264     650      432     321     753      819      644      1463
  Lymphoid leukaemia           801     471     1272     841     493     1335     926     551     1477     1000    603     1604     1535     896      2431
  Myeloid Leukaemia            511     614     1125     534     642     1176     595     727     1323     666     810     1476     1054     1358     2412
  Leukemia unspec.             965     842     1807     1005    891     1896     1131    1027    2157     1295    1188    2483     2226     2169     4395
  Other & unspecified          3692    3965    7657     3921    4232    8153     4573    4971    9543     5358    5793    11151    10582    11026    21607
                                                                                                                                                     
  All sites Total              57558   57426   114985   61288   61495   122783   71759   72496   144255   84045   84679   168723   171494   159675   331169
  All sites but C44^\#^        56761   56677   113438   60435   60683   121117   70742   71523   142265   82840   83519   166358   168854   157369   326223

^\#^Numbers do not include nonmelanoma skin cancer.

###### 

Estimated cancer incidence in the period 2013--2050 and causes of increase.

                                                            2013              2015                2020                2025                 2050
  --------------------------------------------------------- ----------------- ------------------- ------------------- -------------------- --------------------
  Estimated population                                      85294388 (100%)   88487396 (103.7%)   96260017 (112.9%)   103742157 (121.6%)   137872522 (161.6%)
  Number of cases^\#1^                                      114985            122783 (106.8%)     144255 (125.5%)     168723 (146.7%)      331169 (288.0%)
  Increased cases from 2013^\#2^                                              7798 (6.8%)         29270 (25.5%)       53738 (46.7%)        216184 (188.0%)
  Increased cases due to population growth^\#3^                               4303                14783               24869                70880
  Increased cases due to population structure change^\#4^                     3494                14487               28869                145304
  \% Increase due to population growth^\#5^                                   55.20%              50.50%              46.28%               32.79%

N.B.

^\#1^Number of expected cases depending on 2013 rates of incidence.

^\#2^Number of increased cases from 2013 number of cases.

^\#3^Number of increased cases (from 2013) that is attributed to increase in population number (population growth).

^\#4^Number of increased cases (from 2013) that is attributed to change in population structure (aging of population) and not to population growth.

^\#5^Percent of increased number of cases (from 2013) that can be attributed to population growth only (not due to change in population structure).

[^1]: Academic Editor: Lance A. Liotta
